Lv12
50 积分 2022-07-31 加入
Data from Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1)
2天前
已完结
Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial
1个月前
已完结
德曲妥珠单抗所致间质性肺病全程管理策略
1个月前
已完结
Efficacy and safety of neoadjuvant SHR-A1811 with or without pyrotinib in women with locally advanced or early HER2-positive breast cancer: a randomized, open-label, phase 2 trial
1个月前
已完结
Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer
2个月前
已完结
Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study
3个月前
已完结
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
3个月前
已完结
Molecular Characterization and Classification of HER2-Positive Breast Cancer Inform Tailored Therapeutic Strategies
3个月前
已完结
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
3个月前
已完结
Optimizing the safety of antibody–drug conjugates for patients with solid tumours
4个月前
已完结
皖公网安备34019202002308
